Cytokinetics Price Target Raised to $103 From $99 at Mizuho
Why Is Cytokinetics, Incorporated (CYTK) Among the Worst Performing Biotech Stocks in 2024?
Cytokinetics Is Maintained at Outperform by Mizuho
Express News | Cytokinetics Inc : Mizuho Raises Target Price to $103 From $99
Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan
Unusual Options Activity: MET, CNH and Others Attract Market Bets, MET V/OI Ratio Reaches 318.2
EST Nov 20th Afternoon Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options